TransMedics Gr Q1 2024 GAAP EPS $0.35 Beats $0.02 Estimate, Sales $96.850M Beat $83.778M Estimate
Portfolio Pulse from Benzinga Newsdesk
TransMedics Gr (NASDAQ:TMDX) reported Q1 2024 earnings of $0.35 per share, surpassing the $0.02 estimate by 1650%, and a 537.5% increase from last year's losses. Sales reached $96.850M, beating the $83.778M estimate by 15.60%, marking a 133.07% increase from the previous year.
April 30, 2024 | 9:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransMedics Gr reported a significant beat on Q1 2024 earnings and sales, with EPS at $0.35, far exceeding the $0.02 estimate, and sales of $96.850M, surpassing the $83.778M forecast.
The substantial beat on both earnings per share and sales forecasts for TransMedics Gr indicates strong financial performance and operational efficiency, significantly exceeding analyst expectations. This performance, especially being a turnaround from the previous year's losses, is likely to positively influence investor sentiment and could lead to a short-term uptick in TMDX's stock price.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100